XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Adimab Development and Option Agreement (the "Adimab Agreement") - Narrative (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Research and development expense $ 20,881,000 $ 18,527,000
Adimab Agreement    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Research and development expense $ 0 $ 28,000